Acute Kidney Injury Treatment Market Is Expected To Reach a Revenue Of USD 3,818.9 Mn By 2033, at 7.8 % CAGR: Dimension Market Research
11 nov. 2024 13h03 HE
|
Dimension Market Research
New York, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Market Overview The Global Acute Kidney Injury Treatment Market is projected to reach USD 1,944.4 Million by the end of 2024 and is expected to grow...
Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
11 nov. 2024 07h30 HE
|
Arch Biopartners
TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun in...
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins
02 août 2024 07h20 HE
|
Arch Biopartners
Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique...
Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
27 juin 2024 07h25 HE
|
Arch Biopartners
TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that Dalton Pharma Services (Dalton) has completed the...
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
18 juin 2024 07h35 HE
|
Arch Biopartners
TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary’s Conjoint Health...
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
16 avr. 2024 07h14 HE
|
Arch Biopartners
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a...
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
18 mars 2024 07h28 HE
|
Arch Biopartners
British Medical Journal Open publishes paper detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients...
Acute Kidney Injury Market Insights and Forecast to 2032 Reveal Rising Incidence and Need for Advanced Therapeutics
11 mars 2024 10h28 HE
|
Research and Markets
Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Acute Kidney Injury (AKI) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. ...
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
07 mars 2024 07h26 HE
|
Arch Biopartners
TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in...
Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
10 janv. 2024 07h26 HE
|
Arch Biopartners
TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received a No Objection Letter from...